HealthMore in Health→
Pfizer’s Monthly Obesity Drug Keeps Its Case Alive
Key Takeaways
- Detailed midstage data offered further evidence for monthly dosing.
- The obesity drug candidate entered Pfizer through its Metsera acquisition.
- Dosing convenience is emerging as a key differentiator in obesity medicine.
DE
DT Editorial Team··via statnews.com
